Core Viewpoint - aTyr Pharma, Inc. is facing a securities class action lawsuit due to a significant stock drop of 83% following the failure of its drug trial for Efzofitimod, which did not meet its primary endpoint [1][2]. Company Overview - The lawsuit alleges that aTyr and its executives provided materially false and misleading information regarding the efficacy of Efzofitimod, leading to inflated stock prices [2]. - The firm Hagens Berman is leading the litigation and emphasizes the importance of accurate representation of clinical trial data in biotech securities cases [3]. Legal Allegations - The core issue revolves around whether aTyr misrepresented the drug's ability to help patients taper off steroid usage, a critical measure of efficacy [3][5]. - The complaint highlights a gap between the company's optimistic public statements and the actual performance of Efzofitimod in the Phase 3 EFZO-FIT study [4]. Financial Impact - Following the announcement of the trial results, aTyr's stock plummeted from $6.03 to $1.02, reflecting an 83.2% loss on September 15, 2025 [5]. - Investors who purchased shares during the class period (November 7, 2024, through September 12, 2025) and suffered losses are encouraged to submit their claims [6]. Next Steps for Investors - Hagens Berman has a history of securing over $2.9 billion in settlements for investors and is advising affected investors to act before the lead plaintiff deadline of December 8, 2025 [6].